Emcure Pharmaceuticals' shares surged 10% to Rs 1,443 after Kotak Securities upgraded the stock to "buy" with a target price of Rs 1,680, implying a 28% upside potential. The brokerage expects strong growth in the coming quarters, driven by organic performance, in-licensing deals, and robust medium-term prospects.